These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16032731)

  • 1. Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads.
    Enomoto M; Nishiguchi S; Tamori A; Kohmoto M; Habu D; Sakaguchi H; Takeda T; Kawada N; Seki S; Shiomi S
    J Med Virol; 2005 Sep; 77(1):77-82. PubMed ID: 16032731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
    Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
    J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
    Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
    J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
    Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
    Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.
    González V; Padilla E; Diago M; Giménez MD; Solà R; Matas L; Montoliu S; Morillas RM; Pérez C; Planas R
    J Viral Hepat; 2005 Sep; 12(5):481-7. PubMed ID: 16108762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.
    Buti M; Mendez C; Schaper M; Sauleda S; Valdes A; Rodriguez-Frias F; Jardi R; Esteban R
    J Hepatol; 2004 Mar; 40(3):527-32. PubMed ID: 15123370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
    Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL
    J Clin Virol; 2017 Jul; 92():32-38. PubMed ID: 28521211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
    Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
    Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: increase in viral loads in biochemical responders.
    Yoshioka K; Aiyama T; Iwata K; Yano M; Okumura A; Ishikawa T; Kakumu S
    Am J Gastroenterol; 1997 Aug; 92(8):1305-9. PubMed ID: 9260795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
    J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
    Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O
    J Viral Hepat; 2005 Sep; 12(5):473-80. PubMed ID: 16108761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
    Higashimoto M; Takahashi M; Jokyu R; Saito H
    Rinsho Byori; 2006 Feb; 54(2):111-5. PubMed ID: 16548229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.